lymphocytes specific for a variety of tumor-associated peptides that are presented by HLA-A*0201-encoded class I molecules (1-4). To date, 37 sequences have been described that belong to the HLA-A*02 group (5). These variants differ by one or more nucleotides that are almost exclusively localized in exons 2 and 3. Since these two exons encode the a 1 and a 2 domains that form the peptide binding groove of the major histocompatibility complex (MHC) class I molecule and are responsible for the interaction of the peptide-MHC class I complex with the T-cell receptor (TCR) (6, 7), such sequence variations can dramatically influence peptide presentation as well as TCR interactions (2, (8) (9) (10) (11) (12) (13) (14) (15) (16) ). The former HLA-A*0201 allele, now designated as HLA-A*02011 due to the recent discovery of two additional HLA-A*0201 variants (HLA-A*02012 and -A*02013) each carrying a silent substitution in exon 2 (5, 17), is by far the most prevalent allele in Caucasian populations. While the A*02011 allele is predominant in most populations, its frequency varies significantly in groups with different genetic backgrounds (18, 19) . subtypes, such as A*02011, are of central importance it is essential to perform molecular subtyping to assure that a patient carries the correct HLA-A*02 subtype. While typing strategies based on polymerase chain reaction (PCR) amplification and hybridization with sequence-specific oligonucleotide probes (PCR-SSOP) are especially useful for typing large numbers of samples for population studies and bone marrow transplant evaluation (21) (22) (23) (24) , direct sequencing provides an optimal means to identify class I alleles (25) (26) (27) (28) . This technology, however, may not be readily available at a cost effective price for many centers. As an alternative we have developed a PCR-based strategy for selection of HLA-A*02011 individuals that can be easily executed by clinical laboratories.
This typing strategy is a modification of the methodology of Krausa and co-workers who designed a series of PCR primers to identify many different HLA-A*02 subtypes (29, 30) . It is based on the finding that under stringent conditions a single nucleotide mismatch between a 3ø PCR primer and its template will hinder optimal hybridization leading to a subsequent failure to generate a PCR amplicon (31) . Krausa and co-workers Primers and reaction combinations Some primers used in the PCR-SSP approach (Table 2) have been described previously (29, 30) . Other primers and reaction combinations were newly introduced. In each reaction a 333-bp region of the b2-microglobulin (b2-m) gene was amplified as an internal control to certify that the PCR reaction functioned properly. This primer combination has been adapted to our amplification conditions based on previous descriptions (29, 30, 37) .
Material and methods
Five SSP combinations were included in a first typing step (Table 3A, Step 1): the A2-PCR (1/1) and a PCR specifically amplifying A*0209 (1/3) were performed basically as described (29) . A PCR amplifying other HLA-A alleles but excluding the A*02 allele group, with the exception of A*02012, was newly introduced (1/2). (Table 3A) . When relevant, reactions [(2/6)-(2/13)] and [(3/6)-(3/13)] may be used in addition to discriminate several more recently described subtypes from A*02011/3 (Table 3B ).
The specificity and sensitivity of all the core reactions with the exception of reactions (1/5) and (4/4) ( (29, 30, 37) . ham (36). The intron passages are given in brackets and numbered according to Kotsch et al. (25) . 4 Primers newly created to specifically exclude and detect the more recently described subtypes. 2 Primers with AL in their designation are taken from (29, 30) . The other primers are selected These primers have not been directly validated due to lack of corresponding control cell lines. according to Arnett and Parham (36) and the IMGT/HLA-database. Step 2 subtyping reactions. Positivity for A*0207 in reaction (2/2) and A*0217 in (3/1) was verified with reference cell 2 (1/5) may be additionally performed to detect A*02012 which is typed as non-A2 by reaction lines. Positivity for A*0215N and A*0218 in reaction (2/2) can be assumed in analogy to the (1/2) but positive for A2 through FACS analysis. positivity of A*0207 since these three subtypes show the same mismatch with the primer 3 In the core reactions (Table 3A) the underlined alleles A*0224, A*0225, A*0226, A*0229, sequence. Amplification for the subtypes marked in light grey has not been verified (reference A*0230, A*0231, A*0232N and A*0234 are expected to have the same reaction pattern as cell lines not available, reactions not yet validated). A*02011/3. A*02011/3 can be distinguished from these subtypes with the extended typing 5 A*68032 is amplified in reaction (1/1) and therefore is also detected in corresponding approach (Table 3B ). This extended typing approach has not been validated with the subtyping reactions. corresponding control cell lines. Therefore, the specificities listed are theoretical.
6 Due to a common substitution at the 3ø terminus A*0235 is also amplified in reaction (3/13). tures. Activity is regained after the first denaturation step of the PCR. This allowed the handling of all reagents at ambient temperature. Defined primer concentrations and, if necessary, formamide (Sigma-Aldrich, Deisenhofen, Germany) were used as described in Table 3A . 
Technical comments
Due to our basic goal to specifically select A*0201 sequences and discriminate them from other subtypes, primers were chosen to fit the A*0201 sequences as well as possible. Some primers, therefore, show internal mismatches with some subtypes as illustrated in Table 3 quence of the a1-and a2-region and silent substitutions are excluded at the positions considered with reaction (3/1).
Results

FACS analysis as a prescreening for HLA-A2
For clinical studies, the selection of HLA-A*0201-positive patients is made using preselection for HLA-A2-positive individuals by FACS analysis followed by a PCR-based typing in two molecular steps.
To date this combined approach has been applied to more than 85
samples. In the case of negative FACS results with all three A2-specific mabs, molecular typing was not performed. would be detected as HLA-A2 through FACS analysis despite negativity in reaction (1/1) (see below).
PCR-based typing
As shown in Fig. 1 , there are no unique nucleotide substitutions in the HLA-A*0201 (A*02011/2/3) alleles that allow distinction from other class I alleles or from all other HLA-A*02 subtypes. In contrast, there are many substitutions within exons 2 and 3 that are shared not only by different HLA-A*02 subtypes but also by other HLA alleles. Therefore, the HLA-A*0201 (A*02011/2/3) alleles can only be detected through a series of PCR reactions that provide a pattern of reactivity that allows these alleles to be identified. (Table 3A) . (Table 3B) .
Step 1: identification of HLA-A*02-positive individuals heterozygous for HLA-A2. These reactions also reveal the presence or absence of the A*0209 or A*0219 subtypes (see Table 3 , Step 1).
Eight different reactivity patterns can result from this first set of four PCR typing reactions (Table 4A) the primers AL.37 and SG.NA2. Therefore, HLA-A*02012 will not be detected in reaction (1/1) but it will be positive in reaction (1/2).
Since cells expressing this allele, however, will be detected by FACS analysis using HLA-A2-specific mabs, a discrepancy between FACS results and molecular typing in reaction (1/1) would alert one to the possible presence of the A*02012 sequence. Positive identification of this allele could then be verified with the reaction (1/5) suggested in Table 3A . In addition, the A*68032 allele also shows the characteristic A*02-specific thymidine at nucleotide position 78. This substitution leads to amplification of the A*68032 sequence by the A2-PCR. However, subtyping reactions performed in step 2 allow this sequence to be distinguished from that of A*02011 or A*02013. Table 4B summarizes the necessary subtyping reactions according to the reaction patterns identified in step 1.
Step 2: HLA-A*02 molecular subtyping
The polymorphic positions within the A*02 sequence that are detected by the primers used in step 2 are highlighted in Fig Table 3A and Fig. 2A . for the mentioned subtypes in these reactions could not be verified. 1 The more recently described subtypes A*0224/25/26/30/31/32N/34 are not B) Extended subtyping: Listed are the patterns for A*02011/3 and the distinguishable from A*02011/3 using these core reactions, but are separeight more recently defined subtypes using the 16 additional suggested reacately considered in additional reactions (see B). A*0209 is identical with tions [(2/6)-(2/13)] and [(3/6)-(3/13)]. A*02011/3 in the subtyping but distinguishable from A*0201 sequences in 4 SG.N25 has an internal mismatch with A*0226, AL.V with A*0229 and the step 1 reactions.
AL.14 with A*0234. Amplification could not be verified for these subtypes. In an A2/non-A2 heterozygous individual in which the A*02 allele is not HLA-A*0209 (reaction pattern 2 in Table 4A) Table 3 and Fig. 2 for interpretation. Allele determination according (.). LCL controls: DS (A2, A3), JY (A2, A2), OZB (A*0209, A3) and LWAGS to the core typing approach excluding the more recently described sub-(A33, A33) (see also The more recently described subtypes which are not distinguishable from A*02011/3 by the step 2 core reactions are considered separately in Fig. 2B . Suggestions are made for primer combinations that can exclude these additional alleles. This extended subtyping is to be utilized in addition to the core subtyping reactions described above. The primer combinations, however, need to be validated with samples carrying these alleles. Fig. 3 gives some typing examples using the step 1 and step 2 core typing strategy. Evaluation of the results is correlated with patterns designated in Table 4 and Fig. 2A . The first example is a step 1 typing result for the common situation of a sample from a A2/non-A2 heterozygous individual (Fig. 3A) . tive individuals in most populations (18, 19) . Another common grouping of A*02-positive samples is that of a A2/non-A2 heterozygous, A*0205-positive individual as shown in Fig. 3C (18, 19, 21 ).
Selected typing examples
The last example illustrates a particularly interesting typing result.
We found that the cell line T7527 (IHW number 9077) that is designated as homozygous for A*0207 in the IMGT/HLA database (5) appeared also to carry an A*02011 allele (Fig. 3D ). This cell line was previously oligotyped as A*0201 by Gao et al. (24) . The heterozygosity of T7527 for HLA-A*02 was verified by direct sequencing of the A*02 amplicon generated through a modified reaction (1/1) with a biotinylated sense primer (AL.37) in the absence of control primers (data not shown); the sequencing primers used were ASEQ3 and ASEQ5 (25) . This finding is of importance to functional studies that use this cell line since T7527 expresses two different HLA-A*02 subtypes, only one of which is A*02011.
Discussion
As it became evident that effective MHC class I typing could only be done at the molecular level, various approaches with different levels of resolution have been described (42-47). Furthermore, because HLA-A*02 is one of the dominating class I allele groups, various strategies were developed to specifically subtype HLA-A*02 with the main goal to define all subtypes for population genetics and tissue transplantation (21-24, 29, 30) . The strategy described in this paper focusses on the detection of HLA-A*02011. The HLA-A*02 allele group is a popular HLA entity with respect to both frequency and functionality (48, 49) and HLA-A*02011 is momentarily the predominant restriction element utilized as the basis for development of a number of immunotherapies and cancer gene therapies (1-4).
The method described here is rapid and inexpensive and highly adaptable to the needs of clinical studies since single as well as multiple samples can be analyzed on any given day. Approximately half of the samples will be excluded from the molecular typing by the prescreening for HLA-A2 with FACS analysis. In the absence of available cells for flow cytometry generic HLA-A*02 amplification (such as reactions shown in step 1) could be used for prescreening.
The entire molecular procedure takes about 8 h, including 5 h for the first step and 3 h for the second step. The method is based on the A*02 subtyping procedure developed by Krausa and co-workers However, in an A*02 heterozygous individual the following exceptions have to be mentioned: the subtype combination A*02011/3/ A*0208 that shows a step 2 reaction pattern with positivity in reactions [(2/1)-(2/13)], reaction (3/5) and reaction (4/2) (Fig. 2) , cannot be distinguished from the combination A*0205/A*0220, which shows the same reaction pattern (Fig. 2) . A similiar situation exists for the subtype combinations A*02011/3/A*0235 versus A*0211/ A*0234 and A*02011/3/A*0213 versus A*0226/A*0212. In the first three cases special subtype-specific primers are required for exact discrimination. The last situation cannot be distinguished easily by any method described to date, except for direct sequencing. Heterozygosity including the A*0233 subtype is particularly complex as discussed (see legend to Fig. 2) .
Independent of the A*02 typing method used today it has to be taken into consideration that the number of newly discovered HLA alleles is continuously growing and this is particularly dramatic in 
